A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Last Updated February 4, 2025
Want to learn how to participate in this trial?
88998377LYM1001
OVERVIEW
-
Sexes Eligible for Study
all -
Age
years -
Phase
phase 11 -
Sites
Sites -
Status
Recruiting
SUMMARY
The main purpose of this study is to characterize safety and to determine the recommended phase 2 dose (RP2D) for JNJ-88998377 (Part A: Dose Escalation) and to further assess the safety of JNJ-88998377 at the RP2D (Part B: Dose Expansion).
CONDITIONS
- Lymphoma, Non-Hodgkin
- Refractory B-Cell NHL
- Relapsed B-cell NHL
ELIGIBILITY
Inclusion Criteria:
* Participants have histologically or cytologically confirmed B-cell non-Hodgkin's Lymphoma (NHL) according to the 2022 World Health Organization (WHO) classification with relapsed or refractory disease
* Participants have measurable disease or meet all requir
DETAILS
LOCATIONS
| Country (6) | City or Province (10) | Status |
| Japan | Tokyo The Cancer Institute Hospital of JFCR |
RECRUITING
|
| Poland | Katowice Pratia Hematologia Sp z o o |
RECRUITING
|
| Poland | Kielce Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach |
RECRUITING
|
| Taiwan | Taipei National Taiwan University Hospital |
RECRUITING
|
| Taiwan | Taoyuan Linkou Chang Gung Memorial Hospital |
RECRUITING
|
| Türkiye | Ankara Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital |
RECRUITING
|
| Türkiye | Ankara Ankara University Medical Faculty |
RECRUITING
|
| Türkiye | Istanbul Koc University Medical Faculty |
RECRUITING
|
| Italy | Bologna A O U Sant Orsola Malpighi |
RECRUITING
|
| South Korea | Seoul Samsung Medical Center |
RECRUITING
|
35.6895, 139.69171
50.25841, 19.02754
50.87033, 20.62752
25.04776, 121.53185
24.95233, 121.20193
39.91987, 32.85427
39.91987, 32.85427
41.01384, 28.94966
44.49381, 11.33875
37.566, 126.9784
Indicates 50+ sites in this region: click to zoom in.
Indicates 10+ sites in this region: click to zoom in.
Indicates < 10 sites in this region: click to zoom in.
Corresponds to individual site.